TREATMENT OF ADVANCED MYELODYSPLASTIC SYNDROME WITH ALFACALCIDOL
- 29 September 1984
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 324 (8405) , 761
- https://doi.org/10.1016/s0140-6736(84)92676-x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- CLINICAL EVIDENCE FOR 1,25-HYDROXYCHOLECALCIFEROL ACTION IN MYELOFIBROSISThe Lancet, 1984
- A ROLE FOR 1,25-DIHYDROXYVITAMIN D3 IN CONTROL OF BONE-MARROW COLLAGEN DEPOSITION?The Lancet, 1984
- The effect of vitamin D3metabolites on normal and leukemic bone marrow cells in vitroThe International Journal of Cell Cloning, 1984
- Cytarabine: Low-Dose, High-Dose, No Dose?New England Journal of Medicine, 1983
- Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose CytarabineNew England Journal of Medicine, 1983
- 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cellsLeukemia Research, 1983
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982